Altshuler Shaham LTD Sage Therapeutics, Inc. Transaction History

Altshuler Shaham LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $76,996 - $111,243	-1,403 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$70.65 - $96.76 $99,121 - $135,754	1,403 New	1,403 $105,000
Q2 2020 Aug 13, 2020	SELL	$25.95 - $43.15 $5,190 - $8,630	-200 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$26.15 - $77.24 $30,412 - $89,830	-1,163 Reduced 85.33%	200 $6,000
Q4 2019 Feb 11, 2020	BUY	$60.18 - $154.77 $12,036 - $30,954	200 Added 17.2%	1,363 $98,000

Q3 2019 Nov 12, 2019	BUY	$140.29 - $189.96 $6,874 - $9,308	49 Added 4.4%	1,163 $166,000
Q2 2019 Aug 06, 2019	SELL	$157.85 - $183.09 $895,483 - $1.04 Million	-5,673 Reduced 83.59%	1,114 $204,000
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $470,590 - $862,108	5,268 Added 346.81%	6,787 $1.08 Million
Q4 2018 Feb 11, 2019	SELL	$81.94 - $139.71 $2,540 - $4,331	-31 Reduced 2.0%	1,519 $146,000
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $235,832 - $298,111	1,550 New	1,550 $250,000

220

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $730M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

Stay updated on Altshuler Shaham LTD with notifications on news.